Instrument Inactif

Communiqués Amarillo Biosciences, Inc. Other OTC

Actions

AMAR

US02301P2056

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market	16/05	AQ
Ainos : Reports Full Year 2023 Financial Results - Form 8-K	08/03	PU
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th	01/02	AQ
Ainos Announces $1.75 Million Follow-On Funding	25/01	AQ
Ainos, Inc. Announces Stock Consolidation	13/12	AQ
Ainos : Private Placement - Form 8-K	24/11	PU
Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA	07/11	AQ
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement	26/09/23	AQ
With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients	19/09/23	NE
Ainos VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients	19/09/23	AQ
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan	06/09/23	AQ
Ainos : PROMISSORY NOTE EXTENSION AGREEMENT - Form 8-K	22/08/23	PU
Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond	15/08/23	NE
Ainos Reports Second Quarter 2023 Financial Results	14/08/23	AQ
Ainos Celebrates First Listing Anniversary on Nasdaq	11/08/23	AQ
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform for Broader Industry Adoption	10/08/23	AQ
AINOS, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)	11/04/23	AQ
AINOS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	03/04/23	AQ
AINOS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	14/03/23	AQ
Ainos Issues 2023 Shareholder Letter	18/01/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Amarillo Biosciences, Inc. Other OTC

Actions

AMAR

US02301P2056

Communiqués

Filtres